Adalimumab
Brand: Humira®
NICE TA: 329
Indication: Second line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LMMG Recommendation
Disease category: Gastro-intestinal system
Commissioning responsibility: CCG
PbR excluded: Yes
Background
In UC patients who experience intolerance, secondary failure or primary failure with a first line biologic in line with NICE TA329 or TA342, adalimumab should be used in preference to alternative TNF-alpha inhibitors where it is available.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
Gastroenterology Biologics Pathway (Version 1.1) (355.6 KiB)
Decisions of Lancashire local decision making groups:
| NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
|---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |
